

Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma

A thesis

Submitted for partial fulfillment of master degree in clinical oncology and nuclear medicine

By

Muna Sami Jassim

M.B.CH.B

Under Supervision of

Dr. Mahmoud Abbas ELlithy

Assistant Professor of Clinical Oncology & Nuclear Medicine
Faculty of Medicine – Ain Shams University

Dr. Amr Shafik Tawfik

Lecturer of Clinical Oncology & Nuclear Medicine
Faculty of Medicine – Ain Shams University

Dr. Doaa Atef Mohammed

Lecturer of Clinical Oncology & Nuclear Medicine
Faculty of Medicine – Ain Shams University



*Faculty of Medicine
Ain Shams University*

2016

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢



Acknowledgments

*First and foremost, I feel always indebted to **Allah**, the Most Beneficent and Merciful.*

*I wish to express my deepest gratitude and thanks to **Dr. Mahmoud Abbas ELlithy**, Assistant Professor of Clinical Oncology & Nuclear Medicine, Faculty of Medicine – Ain Shams University, for his constructive criticism, unlimited help and giving me the privilege to work under his supervision.*

*My most sincere gratitude is also extended to **Dr. Amr Shafik Tawfik**, Lecturer of Clinical Oncology & Nuclear Medicine, Faculty of Medicine – Ain Shams University, for his enthusiastic help, continuous supervision, guidance and support throughout this work.*

*Words fail to express my appreciation to **Dr. Doaa Atef Mohammed**, Lecturer of Clinical Oncology & Nuclear Medicine, Faculty of Medicine – Ain Shams University, for the efforts and time she has devoted to accomplish this work.*

I would like also to than all members of the Pathology Department, Abbassia Chest Hospital, for their cooperation and great help in this work.

*Last but not least, I can't forget to thank all members of my Family, especially my **Parents** and my **Husband**, for pushing me forward in every step in the journey of my life.*

Candidate

 **Muna Sami**

List of Contents

<i>Subject</i>	<i>Page No.</i>
List of Abbreviations	I
List of Tables.....	iii
List of Figures	v
Introduction	1
Aim of the Work.....	6
Review of Literature	
Malignant Pleural Mesothelioma	7
Pathology	16
Molecular Aspects of Malignant Mesothelioma	24
Diagnosis and Staging of MPM	41
Treatment and Prognosis	53
Patients and Methods.....	68
Results.....	72
Discussion	90
Conclusion and Recommendations.....	100
Summary	102
References	106
Arabic Summary	—

List of Abbreviations

<i>Abbr.</i>	<i>Full-term</i>
BerEp4	: Tumor glycoprotein
bFGF	: Basic fibroblast growth factor
CALGB	: Cancer and Leukemia Group B
CDK	: Cyclin-dependent kinase
CEA	: Carcinoembryonic antigen
CK	: Cytokeratin
CNS	: Central nervous system
CT	: Computed tomography
EGFR	: Epidermal growth factor receptor
EMA	: Epithelial membrane antigen
EMT	: Epithelial to mesenchymal transition
EORTC	: Organisation for Research and Treatment of Cancer
EPP	: Extrapleural pneumonectomy
GCSF	: Granulocyte colony stimulating factor
HIF-1	: Hypoxia-inducible factor 1
HLA	: Human leuckocyte associated Ag
HMFG-2	: Human milk fat globule protein-2
IGF	: Insulin-like growth factor
IHC	: Immunohistochemistry
IL1	: Interleukin 1
IMRT	: Intensity modulated radiotherapy
LDH	: Lactate dehydrogenase
MIF	: Macrophage migration inhibitory factor
MOC-31	: Tumor glycoprotein

List of Abbreviations (Cont.)

<i>Abbr.</i>	<i>Full-term</i>
MPE	: Malignant pleural effusions
MPM	: Malignant pleural mesothelioma
MRI	: Magnetic resonance imaging
NCI	: National Cancer Institute
NF2	: Neurofibromatosis type 2
OS	: Overall survival
P/D	: Pleurectomy/decortications
PDGF	: Platelet-derived growth factor
PET	: FDG18- Positron-emission tomography
PFS	: Progression free survival
PGE2	: Prostaglandin E2
PGF	: Placental growth factor
PIT	: Prophylactic irradiation to intervention tracts
ROS	: Reactive oxygen species
SV40	: Simian virus 40
T2DM	: Type 2 Diabetes mellitus
TGF	: Transforming growth factor
TKIs	: Tyrosin kinase inhibitors
TNF	: Tumor necrosis factor
TTF-1	: Thyroid transcription factor-1
UICC	: Union for International cancer control European
VEGF	: Vascular endothelial growth factor
VHL	: Von Hippel-Lindau
WT	: Wilms tumour gene protein

List of Tables

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (1):	Histopathological classification of mesothelioma.....	19
Table (2):	Antibodies used in the immunohistochemical staining for differential diagnosis between types of mesotheliomas	22
Table (3):	Immunohistochemistry panel for malignant mesothelioma and adenocarcinoma.....	23
Table (4):	The commonest molecular changes involved in the pathogenesis of MPM	25
Table (5):	Endogenous regulators of angiogenesis	34
Table (6):	UICC-6 staging classification of malignant pleural mesothelioma	51
Table (7):	Description of personal and medical characteristics among cases:.....	73
Table (8):	Description of clinical characteristics among cases.....	74
Table (9):	Description of CD 74(T) and (S) among cases.....	75
Table (10):	Means and Medians for progression free Survival among all cases	75
Table (11):	Means and Medians for overall Survival Time among all cases:	77
Table (12):	Comparison between patients with different response as regards Progression free survival (PFS).....	78

List of Tables (Cont.)

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (13):	Comparison between patients with different response as regards overall survival	79
Table (14):	Comparison between patients with different clinical benefit ratio as regards overall survival	81
Table (15):	Relation between CD74 (T) and each of personal, medical and clinical characteristics among cases	82
Table (16):	Relation between CD74 (S) and each of personal, medical and clinical characteristics among cases.....	83
Table (17):	Relation between different combinations of CD74 (T) and (S) and each of personal, medical and clinical characteristics among cases.....	84
Table (18):	Comparison between patients with different combination of CD 74 (T and S) as regards Progression free survival (PFS)	85
Table (19):	Comparison between patients with different combination of CD 74(T&S) marker as regards overall survival	87
Table (20):	Cox regression analysis to study independent factors affecting PFS	88
Table (21):	Cox regression analysis to study independent factors affecting OS	89

List of Figures

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (1):	Asbestos fiber types.....	12
Figure (2):	Gross anatomy of the pleura.....	16
Figure (3):	An autopsy lung case with diffuse thickening of the pleura causing compression of the underlying lung tissue	18
Figure (4):	Microphotograph of epithelioid mesothelioma (H&E stain) Papillo-tubular structure is prominent	19
Figure (5):	Microphotograph of sarcomatoid mesothelioma (H&E stain).	19
Figure (6):	Microphotograph of biphasic mesothelioma (H&E stain).	19
Figure (7):	Hematoxylin and eosin-stained section (medium power) of pleural sarcomatoid malignant mesothelioma subtypes	20
Figure (8):	A schematic diagram indicating the main players in transformation of mesothelial cells to malignant mesotheliomas.....	24
Figure (9):	The canonical NF2 pathway and an alternative pathway via mTOR for affecting the cell cycle.....	26
Figure (10):	Under normal condition, RKIP block the Snail through MAPK inhibition and NF2 stabilization.....	29
Figure (11):	The six different types of vascularisation observed in solid tumors.....	31

List of Figures (Cont.)

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (12):	Posteroanterior chest radiograph shows nodular pleural thickening forming a rind of tumor encasing the right lung.....	45
Figure (13):	Interlobar fissure involvement.....	47
Figure (14):	Malignant mesothelioma	47
Figure (15):	Magnetic resonance imaging (MRI) with malignant mesothelioma shows invasion across the diaphragm by tumor.....	49
Figure (16):	The PFS shorter when the expression of CD74 was high when both tumour and stromal cell combined than those combination with low expression of CD74.....	86
Figure (17):	Combination of tumour and stromal cell with high expression of CD74 had longer overall survival than those with low expression.	87

Introduction

Malignant mesothelioma is a rare aggressive tumour arising from mesothelial cells of the pleural, peritoneal cavity, pericardium and tunica vaginalis of the testis (*Tischoff et al., 2011*).

Mesothelioma is estimated to occur in approximately 2500 people in the United States every year, malignant pleural mesothelioma occur mainly in older men (median age of 72 years), median overall survival is approximately 1 year (*David et al., 2014*).

There are prominent differences in incidence of malignant pleural mesothelioma (MPM) reported from different countries worldwide varying from to 7 per million (Japan) to 40 per million (Australia) inhabitants per year, In Europe the incidence is around 20 per million with large intercountry variation, It is reasonable to accept that these differences are mainly due to differences in historical asbestos import and consumption (*van Meerbeecke et al., 2011*).

Malignant pleural mesothelioma is most common (MPM), whereas malignant peritoneal mesothelioma accounts only for 6-10%, Infrequent sites of origin are the pericardium and tunica vaginalis in 1-2%, malignant mesothelioma shows either diffuse growth pattern or occurs

as a localized tumour mass, Diffuse type represents an aggressive tumour with poor prognosis and is incurable in most cases (*Tischoff et al., 2011*). There are three major types: epithelioid type, sarcomatoid type and biphasic type and the proportion of each is approximately 60, 20 and 20%, respectively. The desmoplastic type is rare probably 1–2% (*Inai, 2008*).

A lot of data indicate a relationship between mesothelioma and asbestos, the latency periods elapsing between first exposure to asbestos and development of mesothelioma are mostly longer than 40Years, Some recent studies show that the risk increases with the duration of exposure, Possible co-factors in the pathogenesis of asbestos-related mesothelioma include genetic predisposition, diets poor in fruit and vegetables, viruses, immune impairment, recurrent serosal inflammation (*Bianchi et al., 2007*).

Although the mechanism of carcinogenesis is not fully understood, Several molecular pathways involved in malignant pleural mesothelioma have been identified; these include cell cycle regulation, apoptosis, growth factor pathways, and angiogenesis, (*Zucalia et al., 2011*).

Hallmarks of asbestos fibres inhalation included early and sustained inflammation causally attributed to initial accumulation of alveolar macrophages promoting the

subsequent generation of reactive oxygen species (ROS) that cause DNA damage and induce cells to proliferate in a chronic inflammatory milieu, that induce mesothelial cells transcription and production of cytokine which critical to the initiation of injury, fibrosis and tumor Thus, the oxidants and growth factors seem to be responsible for both dysregulation of mitogenic signaling and loss of tumor suppressor proteins that may govern malignant mesothelioma pathogenesis (*Comar et al., 2014*).

The tumours require the continuous formation of new blood vessels in order to grow. Malignant mesothelioma cells produce angiogenic factors, such as vascular endothelial growth factor (VEGF) (*Robinson and Lake, 2005*). Macrophage migration inhibitory factor (MIF) and its receptor CD74 found to be associated with angiogenic activity (*McClelland et al., 2009*).

Vascular endothelial growth factors (VEGFs) belong to the platelet-derived growth factor supergene family (*Shibuya, 2013*), Vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) have crucial roles in both physiological and pathological angiogenesis (*Akahashi, 2011*). The blockage of this pathway is a promising therapeutic strategy for inhibiting angiogenesis and tumour growth (*Moreira et al., 2007*).

The expression of receptor-ligand pair is associated with the angiogenic activity that macrophage migration inhibitory factor (MIF) induces expression of angiogenic CXC chemokines by tumour-associated monocytes and that MIF-dependent expression of angiogenic CXC chemokines is one of several major pathways by which cancer tumours induce an angiogenic environment (*McClelland et al., 2009*).

Malignant pleural mesothelioma clinically manifests after decades of initial exposure to etiologic agents, such as asbestos, and presents with nonspecific symptoms such as dyspnea, pain, or weight loss (*Ramalingam and Belani, 2008*). The definite diagnosis can only be established by diagnostic laparoscopy or open surgery along with biopsy to obtain histological examination and immunocytochemical analysis (*Ahmed et al., 2013*). The type of mesotheliomas and stage at diagnosis remain the cornerstone for treatment approach (*Propodisk et al., 2013*).

Factors associated with poor prognosis in patients with MPM include:

Old age, poor performance status (PS), advance disease stage, chest pain thrombocytosis, weight loss, asbestos exposure and long duration of symptoms (*Shuko Nojir et al., 2011*).

National guidelines recommend that patients with MPM be managed by a multidisciplinary team with experience in MPM, Treatment options for patients with MPM include surgery, radiotherapy, and/or chemotherapy (**David et al., 2014**). Currently, malignant pleural mesothelioma therapy is guided by clinical stage and patient characteristics rather than by the histological or molecular features of the tumor (**Zucalia et al., 2011**).

The aim of radical surgery for malignant pleural mesothelioma (MPM) is to achieve greater survival (**Nakas and Waller, 2014**).

This disease is largely unresponsive to conventional chemotherapy or radiotherapy, and most patients die within 10–17 months of their first symptoms (**Zucalia et al., 2011**).

Targeted therapy used in MPM such as antiangiogenesis agents, immunotherapy, signaling pathway inhibitors (**Shukla and Shukla, 2014**), still has an important role in mesothelioma in controlling the symptom and improve quality of life (**Lang-Lazdunskil, 2014**).